Abstract
Background and aimsStudies in animal models have suggested that hepatic steatosis impacts on portal pressure, potentially by inducing liver sinusoidal endothelial dysfunction and thereby increasing intrahepatic resistance. Thus, we aimed to evaluate the impact of hepatic steatosis on hepatic venous pressure gradient (HVPG) in patients with chronic liver disease.Method261 patients undergoing simultaneous HVPG measurements and controlled attenuation parameter (CAP)-based steatosis assessment were included in this retrospective study.ResultsThe majority of patients had cirrhosis (n = 205; 78.5%) and n = 191 (73.2%) had clinically significant portal hypertension (CSPH; HVPG≥10mmHg). Hepatic steatosis (S1/2/3; CAP ≥248dB/m) was present in n = 102 (39.1%). Overall, HVPG was comparable between patients with vs. without hepatic steatosis (15.5±7.5 vs. 14.8±7.7mmHg; p = 0.465). Neither in patients with HVPG (<6mmHg; p = 0.371) nor in patients with mild portal hypertension (HVPG 6–9mmHg; p = 0.716) or CSPH (HVPG≥10mmHg; p = 0.311) any correlation between CAP and HVPG was found. Interestingly, in patients with liver fibrosis F2/3, there was a negative correlation between CAP and HVPG (Pearson’s ρ:-0.522; p≤0.001). In multivariate analysis, higher CAP was an independent ‘protective’ factor for the presence of CSPH (odds ratio [OR] per 10dB/m: 0.92, 95% confidence interval [CI]:0.85–1.00; p = 0.045), while liver stiffness was associated with the presence of CSPH (OR per kPa: 1.26, 95%CI: 1.17–1.36; p≤0.001). In 78 patients, in whom liver biopsy was performed, HVPG was neither correlated with percentage of histological steatosis (p = 0.714) nor with histological steatosis grade (p = 0.957).ConclusionHepatic steatosis, as assessed by CAP and liver histology, did not impact on HVPG in our cohort comprising a high proportion of patients with advanced chronic liver disease. However, high CAP values (i.e. pronounced hepatic steatosis) might lead to overestimation of liver fibrosis by ‘artificially’ increasing transient elastography-based liver stiffness measurements.
Highlights
Non-alcoholic fatty liver disease (NAFLD) is becoming the most prevalent liver disease with 17–46% of adults affected in Western countries.[1]
hepatic venous pressure gradient (HVPG) was comparable between patients with vs. without hepatic steatosis (15.5±7.5 vs. 14.8±7.7mmHg; p = 0.465)
Higher controlled attenuation parameter (CAP) was an independent ‘protective’ factor for the presence of clinically significant portal hypertension (CSPH), while liver stiffness was associated with the presence of CSPH (OR per kPa: 1.26, 95%confidence interval (CI): 1.17–1.36; p 0.001)
Summary
Non-alcoholic fatty liver disease (NAFLD) is becoming the most prevalent liver disease with 17–46% of adults affected in Western countries.[1]. Hepatic overexpression of thromboxane synthase and endothelin-1 were found and the authors suggested sinusoidal endothelial dysfunction as main mechanism responsible for increased intrahepatic vascular resistance.[14] a recent animal model confirmed elevated portal pressure and hyperdynamic systemic circulation in a rat-model with severe steatosis.[15] Human evidence for an impact of ‘simple’ steatosis on portal pressure is limited to a small study including non-cirrhotic NAFLD patients reporting an association of steatosis and elevated portal pressure. We aimed to evaluate the impact of hepatic steatosis on hepatic venous pressure gradient (HVPG) in patients with chronic liver disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
